Company Overview and News
2018-08-23 247wallst - 1
Stocks were indicated to open lower on Thursday morning, though the S&P 500 hit an all-time high earlier in the week. Earnings season is all but over now and was quite strong, with more than 70% of the companies exceeding expectations. Despite the gains in the market, 2018 has been choppy, and investors have seen less reward in buying every dip than they had been used to in recent years. Many investors also are trying to decide how they want their investments positioned ahead of the midterm elections and given international trade concerns.
WFCNP AIY AINV DLTH HALO AGN ITCI MS PLUG AET WFC ARCC AIB ACT ACAD ARU TGT ADI TRI QCOM PFE
This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Sciences' new(ish) chief medical officer was leaving the company six months after taking over the position.
ACAD CERC INOV GILD CERCZ SCMP CERCW
2018-08-15 seekingalpha - 2
On February 12, 2018, Axovant Sciences (AXON) issued a press release noting changes to the management team and Board of Directors. Dr David Hung retired as CEO and Dr Pavan Cheruvu took his place, among other changes. Three and a half months of radio silence followed. What broke the silence? Another press release on May 29 noting additions to the management team and organizational restructuring. Things got interesting on June 6, when AXON reported it had licensed a gene therapy for Parkinson’s disease from Oxford BioMedica and of course made additional management changes.
ACAD OXB OXBDF AXON
2018-08-09 247wallst - 1
August 9, 2018: Here are four stocks trading with heavy volume among 96 equities making new 52-week lows in Thursday’s session. On the NYSE decliners and advancers traded even and on the Nasdaq, advancers led decliners by about 1.05 to 1.
ACAD UPL UPLMQ ELF COTY
The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with their 2018 Q2 earnings call.
2018-08-09 247wallst - 2
The morning roll call of analyst upgrades and downgrades included about 20 companies this Thursday. There are many companies that are falling outside of the strong trends of this earnings season. With about 80% of the S&P 500 having reported earnings for the second quarter of 2018, roughly 70% of those companies are beating expectations. It’s what’s happening with that other 30% of companies that is leaving investors scratching their heads.
SOJA SO ACAD MYL EXTR ELF DLPH
2018-08-09 247wallst - 1
Stocks were indicated to open marginally higher after a weaker producer price index report calmed some inflation fears. Earnings season has been quite strong, with more than 70% of the companies exceeding expectations and 80% of the S&P 500 having reported, and the S&P 500 is quite close to all-time highs again. Still, the volatility in 2018 has created less rewarding trades by buying the dips, which had been so reliable in prior years.
WFCNP EPC YELP ITG ELF ZNGA MYL SCGLF AMAT MS WFC SCGLY CBB ACAD TRI EXTR GLE
2018-08-09 seekingalpha - 1
Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals' Second Quarter 2018 Financial Results Conference Call. My name is Krista, and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. [Operator Instructions]
2018-08-09 zacks - 1
Acadia Pharmaceuticals (ACAD - Free Report) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.
ACAD VNOM COLL AKBA
acad-10q_20180630.htm UNITED STATES
acad-8k_20180630.htm UNITED STATES
2018-08-07 seekingalpha - 1
ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused largely on the marketing of Nuplazid (pimavanserin), to treat hallucinations and delusions associated with Parkinson's disease psychosis, and its clinical development in additional indications. There has been some coverage about the safety of Nuplazid this year which has weighed on the stock. Since ACAD is essentially all in on Nuplazid (Figure 1), anyone taking a position in ACAD needs to consider if the FDA is going to do anything about Nuplazid, such as change the labeling of the drug.
Stocks were indicated to higher on Tuesday after Monday’s recovery rally. Investors have seen a very strong earnings season, with 80% of the S&P 500 reporting earnings and over 70% exceeding expectations. That said, the volatility in 2018 has created a less rewarding “buy every dip” than had been seen in prior years. Many investors are also trying to decide how they want their investments positioned ahead of the midterm elections and with international trade concerns.
Z OBSV ILMN SEAS ALXN AMAT AVGO WMB MS ETSY ABX CBS ALKS ABX WYNN PDCE CBS.A PHM NBIX CBS.WD ACAD ZG TRI CPV BRCM ALDR ALNY
2018-02-15 - Asif
ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system, or CNS, disorders. ACADIA Pharmaceuticals has a portfolio of product opportunities led by its novel drug, NUPLAZID (pimavanserin), which was approved by the U.S. Food and Drug Administration, or FDA, on April 29, 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, or PD Psychosis, and is the only drug approved in the United States for this condition. NUPLAZID is a selective serotonin inverse agonist, or SSIA, preferentially targeting 5-HT2A receptors. Through this novel mechanism, NUPLAZID demonstrated significant efficacy in reducing the hallucinations and delusions associated with PD Psychosis in its Phase III pivotal trial and has the potential to avoid many of the debilitating side effects of existing antipsychotics, none of which are approved by the ...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to ACAD / ACADIA Pharmaceuticals, Inc. on message board site Silicon Investor.
as of ET